TScan Therapeutics, Inc.
TScan Therapeutics, Inc. (TCRX) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · TCRX · as of Jun 9, 2026
Key Statistics
Explore TScan Therapeutics, Inc. Data
tcrx stock data · financialsAnalyst Ratings & Price Target
Full ForecastTotal: 8 · Buy rate: 87.5%
The TCRX analyst consensus is Buy, based on ratings from 8 Wall Street analysts over the past 3 months. The average 12-month price target is $7.50, representing +646.27% upside from the current price of $1.00.
Competitors & Peers
tcrx competitorsTCRX
ACET
ACRV
FBIO
IMUX
LITSAbout TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is a biopharmaceutical enterprise, currently in its preclinical development stage, focused on engineering T cell receptor (TCR) therapies to combat various cancers. The compan…
what is tscan therapeutics, inc. · tcrx stock overview · tscan therapeutics, inc. company profile · who is tscan therapeutics, inc. ceo · tcrx NASDAQ · tscan therapeutics, inc. headquarters · tscan therapeutics, inc. business segments
About Stock Overview & Key Data
TScan Therapeutics, Inc. (TCRX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 16, 2021. As of the latest trading session, TCRX stock price is $1.00, with a market capitalization of $61.4M. The stock has returned — over the past 12 months and — year-to-date.
Frequently Asked Questions
As of the latest trading session, TScan Therapeutics, Inc. (TCRX) stock price is $1.00. The stock is traded on NASDAQ under the ticker symbol TCRX. The 52-week range is $0.88 – $2.57.